RE:RE:RE:RE:Seeking Alpha on recent THTX developmentI've had this same feeling (it might be a whale) as well, but have been hesitant to mention it. If all they are doing is starting a Phase III, it seems they would have kept us much better informed about the progress. I would like to think that what is going on is a major restructuring of TH to take best advantage of their pipeline. Maybe it got to be too big for Luc and he recognized it needed someone with experience with big pharma. Or then again, maybe SPCEO's eternal optimism is contagious and I've caught the bug.
-LT
SPCEO1 wrote: It is completely speculation on my part and long timers here know my wild speculations may be best utilized for enertainment value than investing, but it seems to me there is a decent chance that we have long been foucusing on a catching a decent sized fish in HIV NASH but what we actually have on our line right now is a whale. We know that Grinspoon has a patent pending on something (new and improved egrifta???). We know the JCI article/press release seems to speak to helping in liver diseases in a much broader way than just HIV NASH. The company has described their interactions with the FDA and EMA with regard to the HIV NASH phase II protocol in very favorable ways. Could there be more to this story than we are aware of? There are all kinds of liver diseases or medical conditions related to the liver. What if Egrifta is helpful in one or more of those. Like diabetes or high chloresterol? I believe MDGL is trying to show that their fat burning drug Resmetiron also helps in these areas. What if Egrifta has some fo the the same attributes?
It seems like it has taken a very long time to get from the first announcement of Grinspoon's data to a phase III in HIV NASH. Maybe that is because they have something bigger on the line and needed to work even harder to get the patent situation sorted out first before embarking on something that is bigger than we currently understand?
Some of my wild speculation along these lines was aided by asking some questions of the author of the Liver therapy Forum. She continues to think that Novo Nordisk might be interested in whatever THTX might be working on, or perhaps more appropriately stated, thinking of working on, with Egrifta beyond HIV NASH. She sent along this link to Novo's website to see what they are targeting in their research and you could see why Egrifta, and maybe even more so, the new version of Egrifta that Grinspoon might have devised, be of interest to them:
https://www.novonordisk.com/research-and-development/our-therapy-areas.html qwerty22 wrote: So these guys have a pharma stock watchlist, it seems we are on it. From reading their description of their service they seem to put a lot of value on upcoming milestones and I assume they recognize that in THTX.
We also made it on that recent NASH Index SPCEO mentioned a while back
Why aren't these signs that at least some in the market are taking a little more interest in THTX?
Then you have Leah's response to SPCEO on the recent paper which was if they had the choice they'd be holding this back for a later release. Which suggests they actually have a plan. From her IR perspective this data would have been more powerful if revealed a little later, they are sowing the seeds atm and this 'fertilizer' would have been more useful when the seeds had germinated.
I don't see what's wrong with the idea that there is a little more interest in THTX now. Is it possible that interest starts these recent volume spikes causing the algo's to kick in and give them the size they have?